Piramel Alzheimer's imaging agent gets EU thumbs up
This article was originally published in Clinica
Executive Summary
The EU's CHMP last week granted a positive opinion to marketing for another imaging agent for use in Alzheimer's disease, Piramal Imaging's NeuraCeq (florbetaben). It gave the go-ahead for Lilly and Avid Radiopharmaceuticals' Amyvid (florbetapir F 18 injection in October 2012, which was then the first imaging agent of its kind to be approved in the EU in January this year; Amyvid was approved in the US earlier in April that year. GE Healthcare's similar product Vizamyl (18F flutemetamol) recently received US approval.
You may also be interested in...
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.